Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region
- PMID: 28719461
- DOI: 10.1097/PAS.0000000000000908
Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region
Abstract
Differential diagnosis based on morphology and immunohistochemistry between a clinically nonfunctioning pituitary neuroendocrine tumor (NET)/pituitary adenoma and a primary or secondary NET of nonpituitary origin in the sellar region may be difficult. Serotonin, a frequently expressed marker in the NETs, has not been systematically evaluated in pituitary NETs. Although mutations in ATRX or DAXX have been reported in a significant proportion of pancreatic NETs, the mutational status of ATRX and DAXX and their possible pathogenetic role in pituitary NETs are unknown. Facing a difficult diagnostic case of an invasive serotonin and adrenocorticotroph hormone immunoreactive NET in the sellar region, we explored the immunohistochemical expression of serotonin, ATRX, and DAXX in a large series of pituitary endocrine tumors of different types from 246 patients and in 2 corticotroph carcinomas. None of the pituitary tumors expressed serotonin, suggesting that serotonin immunoreactive sellar tumors represent primary or secondary NETs of nonpituitary origin. Normal expression of ATRX and DAXX in pituitary tumors suggests that ATRX and DAXX do not play a role in the pathogenesis of pituitary endocrine tumors that remain localized to the sellar and perisellar region. A lack of ATRX or DAXX in a sellar NET suggests a nonpituitary NET, probably of pancreatic origin. One of the 2 examined corticotroph carcinomas, however, demonstrated negative ATRX immunolabeling due to an ATRX gene mutation. Further studies on a larger cohort of pituitary carcinomas are needed to clarify whether ATRX mutations may contribute to the metastatic potential in a subset of pituitary NETs.
Similar articles
-
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.Mod Pathol. 2012 Jul;25(7):1033-9. doi: 10.1038/modpathol.2012.53. Epub 2012 May 11. Mod Pathol. 2012. PMID: 22575867 Free PMC article.
-
Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.Scand J Gastroenterol. 2016 Aug;51(8):994-9. doi: 10.3109/00365521.2016.1170195. Epub 2016 May 10. Scand J Gastroenterol. 2016. PMID: 27162024
-
Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.Hum Pathol. 2016 Oct;56:93-100. doi: 10.1016/j.humpath.2016.06.006. Epub 2016 Jun 21. Hum Pathol. 2016. PMID: 27342911
-
Differential diagnosis of sellar masses.Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi. doi: 10.1016/s0889-8529(05)70058-x. Endocrinol Metab Clin North Am. 1999. PMID: 10207686 Review.
-
The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.Hum Pathol. 2022 Nov;129:11-20. doi: 10.1016/j.humpath.2022.07.015. Epub 2022 Jul 21. Hum Pathol. 2022. PMID: 35872157 Review.
Cited by
-
Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review.Front Oncol. 2018 Nov 6;8:510. doi: 10.3389/fonc.2018.00510. eCollection 2018. Front Oncol. 2018. PMID: 30460199 Free PMC article.
-
Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.Acta Neuropathol. 2024 Nov 23;148(1):68. doi: 10.1007/s00401-024-02836-5. Acta Neuropathol. 2024. PMID: 39580368 Free PMC article.
-
Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.J Clin Endocrinol Metab. 2021 Mar 25;106(4):1183-1194. doi: 10.1210/clinem/dgaa749. J Clin Endocrinol Metab. 2021. PMID: 33106857 Free PMC article.
-
ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature.Endocrine. 2022 Apr;76(1):228-236. doi: 10.1007/s12020-021-02954-0. Epub 2022 Feb 16. Endocrine. 2022. PMID: 35171439 Free PMC article. Review. No abstract available.
-
Loss of ATRX Protein Expression in an Aggressive Null Cell Pituitary Tumor.JCEM Case Rep. 2024 Aug 6;2(8):luae143. doi: 10.1210/jcemcr/luae143. eCollection 2024 Aug. JCEM Case Rep. 2024. PMID: 39108605 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical